RNS Number : 8634R

Evgen Pharma PLC

11 March 2021

Evgen Pharma plc

("Evgen" or the "Company")

Update on Data Safety Review for STAR COVID-19 trial

Review of Patient Safety and Data Quality confirms no concerns with trial

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that after a review of the first 60 patients enrolled, the Data Safety Monitoring Committee ("DMC") for the STAR COVID-19 ("SFX-01 Treatment for Acute Respiratory infections") trial has concluded that there are no concerns regarding patient safety or data quality that would prevent continuation of the trial.

The Phase II/III trial is a double blind, randomised, placebo-controlled study of the Company's lead asset, SFX-01, in patients with acute respiratory distress syndrome ("ARDS"). The trial is co-sponsored by the University of Dundee and NHS Tayside and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or other respiratory infections causing community-acquired pneumonia.

Following this positive step, the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in-patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during Q2 of the calendar year 2021.

Completion of recruitment to the STAR trial is anticipated at the end of 2021/early 2022, assuming there are no substantial changes in the total patients to be recruited.

Dr Huw Jones, CEO of Evgen, commented : "We are pleased with the conclusion of the data monitoring committee with regard to safety and data quality in the STAR COVID 19 study. The former conclusion reinforces what we know about the positive safety and tolerability of SFX-01 from previous studies and the latter is yet another testament to the excellent work carried out by Professor James Chalmers and his colleagues at Dundee under challenging circumstances."

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.


  Evgen Pharma plc www.evgen.com                                        via Walbrook 
  Dr Huw Jones, CEO 
  Richard Moulson, CFO 
  finnCap www.finncap.com                                        +44 (0)20 7220 0500 
  Geoff Nash / Teddy Whiley (Corporate 
  Alice Lane (ECM) 
  Walbrook PR                             +44 (0)20 7933 878 or evgen@walbrookpr.com 
                                                   +44 (0)7876 741 001 / +44 (0)7980 
  Anna Dunphy / Paul McManus                                                 541 893 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

March 11, 2021 02:00 ET (07:00 GMT)